PMV Pharmaceuticals sets underwritten equity offering with TD Securities
PMV Pharmaceuticals entered an underwriting agreement with TD Securities for an underwritten offering of common stock, pre-funded warrants, and accompanying common stock warrants, expected to close Sep 02, 2026.
PMV Pharmaceuticals entered into an underwriting agreement with TD Securities for an underwritten offering of common stock, pre-funded warrants and accompanying common stock warrants. The transaction is expected to close on Sep 02, 2026. The deal includes 22,055,000 shares and 19,900,000 pre-funded warrants.